Rilapladib
- Generic Name
- Rilapladib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C40H38F5N3O3S
- CAS Number
- 412950-08-4
- Unique Ingredient Identifier
- O14CWE893Z
- Background
Rilapladib is the third genomics-derived small molecule drug arising from the Human Genome Sciences-GlaxoSmithKline collaboration to enter clinical development. It is a lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques.
- Indication
Investigated for use/treatment in atherosclerosis and cardiovascular disorders.
- Associated Conditions
- -
- Associated Therapies
- -
No trials found
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath